MOH's National Population Health Survey 2024 reported diabetes prevalence of 9.1% among Singapore residents aged 18 to 74, with prevalence rising with age. Type 2 diabetes is now treated with a much wider toolkit than the metformin-plus-sulfonylurea regimens of a decade ago, and newer drug classes can support weight, cardiovascular and kidney outcomes alongside glucose control. This guide explains the medications used in Singapore, when each is appropriate, and what to monitor.
How diabetes medications work
The goal of treatment is to keep HbA1c (average glucose over the previous 8–12 weeks) at target while avoiding hypoglycaemia and supporting weight, cardiovascular and kidney outcomes. ACE guidance and the Healthier SG Diabetes Mellitus Care Protocol use individualised targets:
- Most adults: HbA1c < 7.0%
- Younger, newly diagnosed, no complications: HbA1c < 6.5%
- Frail elderly, hypoglycaemia-prone, multiple comorbidities: HbA1c 7.5–8.0%
Modern Singapore prescribing increasingly chooses drugs based on the patient's comorbidity profile, not just glucose level. A patient with diabetes plus heart failure may be considered for an SGLT2 inhibitor early; a patient with obesity may be considered for a GLP-1 receptor agonist. These choices are made because selected agents deliver glucose control alongside cardiovascular, renal or weight benefits.
Oral therapies
1. Metformin
First-line in nearly every newly diagnosed type 2 diabetes patient unless contraindicated. Reduces hepatic glucose production and improves insulin sensitivity. Dose: start 500 mg once or twice daily with food, titrate to 1,000 mg twice daily over 2–4 weeks. Extended-release (metformin XR) once daily is better tolerated by patients with GI side effects.
Strengths: weight neutral or slight loss, low hypoglycaemia risk, very low cost, robust outcome evidence.
Watch for: nausea, diarrhoea (improves over 1–2 weeks), B12 deficiency on long-term use (check yearly).
Avoid in: eGFR below 30 mL/min, acute kidney injury, severe heart failure decompensation.
2. SGLT2 inhibitors (gliflozins)
Block glucose reabsorption in the kidney, causing glucose to be excreted in urine. Available in Singapore: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin.
Strengths: proven cardiovascular event reduction, heart failure hospitalisation reduction, kidney protection, modest weight loss (2–4 kg), low hypoglycaemia risk on monotherapy.
Watch for: genital fungal infections (more common in women and uncircumcised men), urinary tract infections, modest volume depletion in the first weeks (especially if also on diuretics), and rare diabetic ketoacidosis even with normal glucose ("euglycaemic DKA") — withhold during major illness or surgery.
Special note: SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c.
3. DPP-4 inhibitors (gliptins)
Prolong incretin hormone activity, increasing insulin release after meals. Available in Singapore: sitagliptin, linagliptin, vildagliptin, saxagliptin, alogliptin.
Strengths: weight neutral, low hypoglycaemia risk, well tolerated, useful in elderly and patients with renal impairment (linagliptin needs no dose adjustment).
Watch for: rare pancreatitis (stop and assess if severe abdominal pain), small heart failure risk with saxagliptin (avoid in heart failure).
4. Sulfonylureas
Stimulate insulin secretion regardless of meals. Common in Singapore: gliclazide MR 30–120 mg/day, glimepiride 1–4 mg/day. Older agents (glibenclamide) are now avoided in favour of gliclazide MR.
Strengths: cheap, effective (lowers HbA1c by 1.0–1.5%), familiar to most clinicians.
Watch for: hypoglycaemia (especially in the elderly, those with irregular meals, fasting during Ramadan), modest weight gain (1–3 kg).
Best for: patients with very high HbA1c needing rapid glucose reduction, those who cannot afford newer drugs, those needing add-on therapy without injection.
5. Thiazolidinediones
Pioglitazone — improves insulin sensitivity. Now used selectively because of fluid retention, weight gain and a small bladder cancer signal. Useful in selected patients with non-alcoholic fatty liver disease.
Injectable therapies
GLP-1 receptor agonists
Slow gastric emptying, increase insulin response to meals, suppress glucagon and reduce appetite centrally. Available in Singapore: liraglutide (daily injection), dulaglutide (weekly injection), semaglutide (weekly injection or daily oral tablet — Rybelsus), exenatide.
Strengths: proven cardiovascular benefit (semaglutide, liraglutide, dulaglutide), substantial weight loss (5–10% of body weight, even more with semaglutide 2.4 mg / tirzepatide), low hypoglycaemia risk.
Watch for: nausea and reduced appetite in the first 4–8 weeks (titrate slowly), rare pancreatitis, retinopathy progression in patients with pre-existing retinopathy and rapid HbA1c drop.
Special note: tirzepatide (Mounjaro), a combined GIP/GLP-1 dual agonist, is registered in Singapore for type 2 diabetes and weight management. The National Drug Formulary currently lists tirzepatide with no subsidy information or financing scheme, so access and cost should be checked at prescribing time.
Insulin
The most potent glucose-lowering treatment. Categories used in Singapore:
- Basal insulin (insulin glargine, detemir, degludec) — once-daily injection, smooth 24-hour cover. Usually started when oral therapy plus a GLP-1 agonist isn't enough.
- Prandial (bolus) insulin (insulin lispro, aspart, glulisine) — rapid-acting, taken with meals.
- Premix insulin (NovoMix 30, Humalog Mix 25) — combines basal and bolus in fixed ratios; convenient for patients who prefer fewer injections.
- Concentrated insulins (U-200, U-300) — for patients needing high daily doses.
Watch for: hypoglycaemia, weight gain, injection-site lipohypertrophy (rotate sites). Patient education on glucose monitoring, dose adjustment and sick-day rules is essential.
Combination therapy strategies
Most patients eventually need more than one drug. A typical Singapore escalation pathway:
- Step 1: Metformin alone.
- Step 2: Add SGLT2 inhibitor (preferred if cardiovascular disease, heart failure or CKD) or GLP-1 agonist (preferred if obesity).
- Step 3: Add a third oral (DPP-4 inhibitor, sulfonylurea) or basal insulin.
- Step 4: Intensify insulin to basal-bolus or premix regimen.
Fixed-dose combinations (e.g., metformin + sitagliptin, metformin + empagliflozin, metformin + linagliptin) reduce pill burden and improve adherence.
Monitoring schedule
- HbA1c every 3 months until at target, then every 6 months.
- Renal function (creatinine, eGFR, urine albumin-creatinine ratio) annually.
- Diabetic eye screen annually (free for Singaporeans through Diabetic Retinopathy screening at polyclinics).
- Diabetic foot screen annually.
- Lipid panel annually.
- BP every visit.
Special populations
- Pregnancy: metformin and insulin are safe. Sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, DPP-4 inhibitors are stopped before or in early pregnancy.
- CKD: metformin OK down to eGFR 30; SGLT2 inhibitors have proven kidney benefit and can be continued to eGFR 20; linagliptin needs no adjustment.
- Older adults: avoid sulfonylureas and basal-bolus insulin where possible (hypoglycaemia risk); set relaxed HbA1c target (7.5–8.0%) if frail.
- Ramadan fasting: avoid sulfonylureas and prandial insulin during fast hours; metformin, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 agonists are generally compatible with fasting.
Hypoglycaemia management
If blood glucose drops below 4 mmol/L:
- Take 15 g of fast-acting carbohydrate (3 glucose tablets, 150 ml fruit juice, or a tablespoon of honey).
- Re-check after 15 minutes; repeat if still below 4 mmol/L.
- Once recovered, eat a small carbohydrate-protein snack if the next meal is more than an hour away.
- Severe hypoglycaemia (loss of consciousness or seizure) needs A&E or glucagon injection if available.
Frequent hypoglycaemia is a reason to de-intensify treatment, not push harder.
MediSave and adherence
Type 2 diabetes is covered under the MediSave Chronic Disease Management Programme (CDMP). Under the current MediSave500/700 scheme, patients may use up to S$500/year from MediSave for outpatient treatment of selected chronic conditions, or S$700/year if they meet the complex chronic disease criteria. Generic metformin and gliclazide are usually inexpensive; SGLT2 inhibitors, GLP-1 agonists and other newer agents cost more, with subsidy depending on the current public-sector and Healthier SG drug lists.
When to see a doctor
Speak to a doctor if:
- HbA1c is above target after 3 months on current therapy.
- You have frequent hypoglycaemia (more than twice a week).
- You have unexplained weight loss, excessive thirst, frequent urination, blurred vision or recurrent infections — possible diabetes decompensation.
- You have foot numbness, non-healing sores or symptoms of nerve, eye or kidney complications.
- You are planning pregnancy on any non-metformin/insulin agent.
- You feel unwell with vomiting, dehydration or fever — sick-day rules may require pausing certain medications (especially SGLT2 inhibitors and metformin).
A short teleconsult is usually enough to review your HbA1c, blood glucose log and current medication, adjust doses, and arrange MediSave-claimable refills. $15 nett with an SMC-registered GP; same-day medication delivery available.
Frequently asked questions
Will starting insulin mean I am 'failing' my treatment?
No. Type 2 diabetes is progressive, and pancreatic beta-cell function naturally declines over years. About half of patients need insulin within 10–15 years of diagnosis. Insulin is a treatment, not a punishment — and modern regimens with basal insulin or fixed-ratio combinations are simpler and safer than the older twice-daily premix routines.
Do GLP-1 drugs like Ozempic work for diabetes?
Yes — semaglutide (Ozempic) is licensed for type 2 diabetes in Singapore and can lower HbA1c alongside weight loss in suitable patients. The same molecule at a higher dose (Wegovy) is licensed for obesity. Tirzepatide (Mounjaro) is a dual GIP/GLP-1 agent registered for type 2 diabetes and weight management; suitability, cost and availability should be checked with the prescriber.
Can I stop my diabetes medication if my HbA1c is back to normal?
Sometimes — patients with newly diagnosed diabetes who lose significant weight (typically 10–15% of body weight) can achieve remission, defined as HbA1c below 6.5% off all glucose-lowering medication for at least 3 months. Most other patients need continued treatment; stopping is usually followed by glucose rising again over months.
Are there any natural alternatives to diabetes medication?
Diet, weight loss, exercise and structured education are the most powerful 'non-pharmacological' interventions and should sit alongside medication, not replace it. Supplements like cinnamon, berberine and bitter melon have small effects but variable quality, and none have outcome evidence comparable to the modern drug classes.
Does MediSave cover diabetes medications in Singapore?
Yes — type 2 diabetes is one of the chronic conditions covered under the MediSave CDMP. Patients can use up to S$500/year, or S$700/year if they meet the complex chronic disease criteria, from their own or a family member's MediSave account towards consultations and approved medications.
Sources reviewed
- MOH: National Population Health Survey 2024 Report
- ACE: Type 2 diabetes mellitus - personalising management with non-insulin medications
- Healthier SG Primary Care Pages: Diabetes Mellitus Care Protocol
- ACE: SGLT2 inhibitors for type 2 diabetes mellitus
- ACE: GLP-1 receptor agonist injections for type 2 diabetes mellitus
- National Drug Formulary: Tirzepatide
- CPF: Using MediSave for outpatient treatments
The bottom line
Most patients with type 2 diabetes reach target HbA1c on a combination of metformin plus one or two newer agents — typically an SGLT2 inhibitor or GLP-1 agonist if they have cardiovascular risk or obesity. The biggest determinants of outcome are adherence, regular review and structured lifestyle support, not the brand of medication.
If you would like a Singapore-licensed GP to review your HbA1c, optimise your regimen and arrange MediSave-claimable refills, you can book a $15 nett teleconsult and have your medication delivered the same day.
